(FQAL) Fidelity Quality Factor - Overview
Etf: Large-Cap, Mid-Cap, Quality, Stocks, US
Dividends
| Dividend Yield | 1.20% |
| Yield on Cost 5y | 2.03% |
| Yield CAGR 5y | 6.53% |
| Payout Consistency | 100.0% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 13.6% |
| Relative Tail Risk | 4.43% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.63 |
| Alpha | 0.80 |
| Character TTM | |
|---|---|
| Beta | 0.861 |
| Beta Downside | 0.837 |
| Drawdowns 3y | |
|---|---|
| Max DD | 16.87% |
| CAGR/Max DD | 1.14 |
Description: FQAL Fidelity Quality Factor January 19, 2026
The Fidelity® Quality Factor ETF (FQAL) allocates at least 80% of its assets to securities that track the Fidelity U.S. Quality Factor Index, targeting large- and mid-cap U.S. companies that exhibit superior quality metrics-such as high return on equity, stable earnings, and low leverage-relative to the broader market. The fund also holds lending securities to generate additional income.
Key data points (as of the latest filing) include an expense ratio of 0.35%, total assets under management of roughly $1.2 billion, and a dividend yield near 1.5%. The ETF’s sector weighting is tilted toward information technology and health care, sectors that have historically benefited from the quality tilt during periods of rising interest rates because their cash-flow stability reduces financing risk. A primary driver of performance is the macro-environment for corporate earnings; stronger GDP growth and tighter labor markets tend to boost the profitability metrics that the quality factor emphasizes.
For a deeper dive into how FQAL’s quality tilt aligns with broader market dynamics, you might explore ValueRay’s analytical tools.
What is the price of FQAL shares?
Over the past week, the price has changed by +0.42%, over one month by +0.81%, over three months by +4.26% and over the past year by +14.22%.
Is FQAL a buy, sell or hold?
What are the forecasts/targets for the FQAL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 89.9 | 16.7% |
FQAL Fundamental Data Overview February 04, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.16b USD (1.16b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.16b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.16b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.09% (E(1.16b)/V(1.16b) * Re(9.09%) + (debt-free company))
Discount Rate = 9.09% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)